
    
      This study (MI-CP138) is a Phase 2a, randomized, double-blind, placebo-controlled,
      multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic
      asthma. Approximately three investigative sites in Canada will participate in this study,
      with up to 40 evaluable patients randomized in a 1:1 ratio to receive MEDI-528 (9.0 mg/kg) or
      placebo as a single IV infusion.
    
  